Prezzo e rimborso dei farmaci in caso di estensione delle indicazioni: i risultati di una survey sui soci di ISPOR Italy Rome Chapter [0.03%]
意大利药物报销协会关于药品适应症扩展的价格和补偿的调查结果
Eugenio Di Brino,Claudio Jommi
Eugenio Di Brino
Costo-efficacia di IMI/CIL/REL rispetto a CMS+IMI per il trattamento di infezioni batteriche Gram-negative non sensibili ai carbapenemi [0.03%]
IMI/CIL/REL与CMS+IMI治疗对碳青霉烯类耐药的革兰阴性菌感染的成本效益分析
Martina Paoletti,Andrea Marcellusi,Joe Yang et al.
Martina Paoletti et al.
Analisi di impatto sul budget sanitario italiano di enzalutamide per il trattamento del carcinoma prostatico metastatico ormono-sensibile [0.03%]
恩扎卢特胺治疗激素敏感性转移性前列腺癌对意大利卫生预算的影响分析
Francesca Fiorentino,Paolo Di Rienzo
Francesca Fiorentino
Il ruolo degli esiti riferiti dal paziente nelle decisioni di rimborso e innovatività dei farmaci in Italia [0.03%]
意大利患者报告结果在药品报销和创新中的作用
Francesco Malandrini,Cesare Borroni,Michela Meregaglia et al.
Francesco Malandrini et al.
Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis [0.03%]
成本最小化分析支持射频超声多谱仪（REMS）诊断骨质疏松的卫生技术评估
Ludovica Borsoi,Patrizio Armeni,Maria Luisa Brandi
Ludovica Borsoi
Introduction: A timely diagnosis of osteoporosis is key to reducing its growing clinical and economic burden. Radiofrequency Echographic Multi Spectrometry (REMS), a new diagnostic technology using an ultrasound approach,...
Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still's Disease [0.03%]
Erratum in: 在Still疾病的治疗中对anakinra预算影响分析的勘误
Roberto Ravasio,Roberto Giacomelli,Stefano Bianchi
Roberto Ravasio
[This corrects the article DOI: 10.33393/grhta.2020.2140.]. Copyright © 2020, The Authors.
Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update [0.03%]
意大利B型血友病治疗中长效重组IX因子产品的成本分析：最新进展
Andrea Aiello,Maria E Mancuso,Serena Leone et al.
Andrea Aiello et al.
Haemophilia B (HB) is a rare disease which may lead to chronic disabling arthropathy, resulting in a significant clinical, social and economic impact. In recent years, new extended half-life (EHL) factor IX concentrates produced by recombin...
Disability weights for castration-resistant prostate cancer: an empirical investigation [0.03%]
前列腺癌去势抵抗性疾病的致残权重值：实证研究
Ludovica Borsoi,Oriana Ciani,Rocco De Vivo et al.
Ludovica Borsoi et al.
Introduction: Health state valuation and diagnostic-therapeutic pathways at the junction between non-metastatic and metastatic castration-resistant prostate cancer (CRPC) are not well documented. We aimed at: (i) estimati...
How reliable are ICER's results published in current pharmacoeconomic literature? The controversial issue of price confidentiality [0.03%]
ICER在现行药物经济学文献中发布的数据的可靠性？价格保密性的争议问题。
Pierluigi Russo
Pierluigi Russo
Pharmacoeconomic data are widely used along drug life cycle for supporting decision-making processes on research and development, pricing and reimbursement, and market access. In this context, the incremental cost-effectiveness ratio (ICER)...
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain [0.03%]
多准则决策分析（MCDA）应用于西班牙遗传性血管性水肿的三种长期预防治疗中
Néboa Zozaya,Teresa Caballero,Teresa González-Quevedo et al.
Néboa Zozaya et al.
Introduction: Hereditary angioedema (HAE) is a rare genetic disease that impairs quality of life and could be life-threatening. The aim of this study was to apply a multicriteria decision analysis to assess the value of t...